BioSpace News Archive

Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo - controlled study usin g nomacopan for treatment of BP Phase III study in both the U.S. and Europe expected to begin in H1 2021 Nomacopan has been granted orphan drug designation for treatment of BP in the U.S. and Europe

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

RetinalGeniX™ Technologies, Inc. www.retinalgenix.com announced today the launch of its RetinalCam™ Home Monitoring & Physician Alert System

Entos is working with Applied Pharmaceutical Innovation (API) to ensure secure supply of inputs for its vaccine production and the ability to expand its Edmonton facilities. API has been providing Entos with enhanced capacity to support its growing team.

MedSelect leverages Prime’s novel medical drug management strategy to drive appropriate use of medical benefit drugs, cost effectiveness and better health outcomes

Genome & Company (KONEX: 314130), a global pioneer company of microbiome therapeutics, initiated clinical trials of GEN-001, an anti-cancer microbiome therapeutic (NCT04601402).

- Influenza A (IVA) animal model confirmed 75% clinical symptom improvement compared to the control group - Broad antiviral efficacy results against SARS-CoV-2 and IVA were presented at the ISIRV-AVG conference

In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020.

-- Company recently licensed cellular therapy for potential treatment of ARDS associated with COVID-19 -- Mino-Lok, Company’s lead product, is progressing through Phase 3 trials and, if approved, is positioned for market entry into an estimated $1.5 billion market -- Phase 2b trial for Halo-Lido hemorrhoid treatment expected to begin Q1 2021

In a first of its kind international partnership, SATT Paris-Saclay, the Technology Transfer Accelerator Office of one of the world’s leading innovation clusters, and Valent BioSciences LLC, the worldwide leader in the development, manufacturing, and commercialization of biorational products, signed a joint agreement to develop breakthrough sustainable biopesticide technologies for agricultural applications. Util